基因模拟GLP-1受体激动症和大脑小血管疾病
Panagiotis Zangas1, Murad Omarov1, Marios K Georgakis1,2,3
1Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Germany.
模仿葡萄糖类-1受体 (GLP-1R) 激动剂的基因变异与小血管中风和白质过强度风险的降低有关. 这表明GLP-1R激素可能为脑小血管疾病 (cSVD) 提供新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 大脑小血管疾病 (cSVD) 是中风和痴呆的主要原因,没有有效的治疗方法.
- 葡萄糖类-1受体 (GLP-1R) 激动剂是已知的糖尿病和肥胖的治疗方法,具有已知的心血管益处.
研究的目的:
- 调查模仿GLP-1R激动剂作用和cSVD表型的遗传变异之间的关联.
- 探索GLP-1R激素在减轻cSVD负担方面的潜力.
主要方法:
- 通过在GLP1R基因附近使用单核酸多态 (SNP) 进行了药物标孟德尔随机化 (MR) 分析.
- 主要结局包括小血管中风和白质超强度 (WMH) 体积,使用逆方差加权MR分析.
主要成果:
- 通过降低HbA1c对GLP-1R激素的基因模仿与小血管中风和减少WMH体积的几率显著降低有关.
- 在基因代理GLP-1R驱动的BMI降低中观察到类似的保护性关联.
结论:
- 基因代理GLP-1受体激动症与临床和成像cSVD结果的负担较低有关.
- 这些发现支持研究GLP-1受体激动剂用于cSVD预防的临床试验的理由.
更多相关视频
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
06:14Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
Published on: May 8, 2018
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pharmacogenomics: Identification of New Drug Targets
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
GPCRs Regulate Adenylyl Cylase Activity
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Dipeptidyl Peptidase 4 Inhibitors
